Daxor Corporation to Exhibit at the Society for Critical Care Medicine 48th Congress

Tailwinds' Take: Looking forward to seeing more data on the BVA-100. The medical community is just waking up to the incredible savings in mortality...

Daxor Emerges

Accurate blood volume monitoring can save lives and reduce medical costs The BVA 100 is the only approved product on the market Hospitals...

Daxor Corporation Appoints Guido Manzo, Vice President of Sales

NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement...

Daxor Corporation Announces Acquisition of BVA-100® Blood Volume Analyzer to Aspirus Wausau Hospital in...

NEW YORK, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood...

New Data Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) in Evaluation...

NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.